Shareholder information

Ordinary shares

The Company's shares are listed on the London Stock Exchange (LSE).

REGISTRAR
The Company's share register is administered by Lloyds TSB Registrars, which also provides the following services:

• GlaxoSmithKline Investment Plan enables shareholders to reinvest quarterly dividends and/or make monthly investments in the Company's ordinary shares using a special dealing arrangement.
• GlaxoSmithKline Individual Savings Account is a tax-efficient way to invest in the Company's ordinary shares.
• GlaxoSmithKline Corporate Sponsored Nominee provides a facility for shareholders to hold shares without the need for share certificates. Shareholders' details will not be held on the main share register, and so will remain confidential.
• Shareview service provides shareholders with information on their investment in the Company. Shareholders may register for this service at www.shareview.co.uk.
• Shareview dealing service is a telephone and internet share dealing facility available to ordinary shareholders by logging on to www.shareview.co.uk/dealing or by calling 0870 850 0852.

American Depositary Shares

The Company's shares are listed on the New York Stock Exchange (NYSE) in the form of American Depositary Shares (ADSs) and these are evidenced by American Depositary Receipts (ADRs), each one of which represents two ordinary shares.

In general, the NYSE's rules permit the Company to follow UK corporate governance practices instead of those that apply in the US, provided that the Company explains any significant variations. This explanation is provided on the Company's website.

ADR PROGRAMME ADMINISTRATOR
The ADR programme is administered by The Bank of New York, which provides Global BuyDIRECT, a direct ADS purchase/sale and dividend reinvestment plan for ADR holders.

SHARE DEALING SERVICE
Hoare Govett Limited operates a postal dealing service in the Company's ordinary shares. It enables investors to buy or sell shares at competitive commission charges. Transactions are executed and settled by Pershing Securities Limited. Further details of this service, together with purchase and sale forms, may be obtained by telephoning +44 (0) 207 661 6555.

Smith Barney, part of Citigroup, also offers a share dealing service in the Company's ordinary shares and ADSs. Further details of this service can be obtained by contacting their offices in the UK or US (see contact details for further information).

The provision of the details above are not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing, should be obtained from a stockbroker or independent financial adviser.

SHARE PRICE INFORMATION
Share price information is available on the website at www.gsk.com. Information made available on the website does not constitute part of this Annual Review. Information in the UK is also available on Ceefax, Teletext, and from FT Cityline by calling 0906 003 5694 or 0906 843 5694 (calls charged at 60p a minute plus VAT at all times).

Share buy-back programme

In October 2002, following the completion of the first £4 billion share buy-back programme announced in 2001, the Company announced plans for a new £4 billion share buy-back programme. Of this second programme £219 million was accounted for in 2002, £980 million in 2003 and £1,000 million in 2004. The programme covers purchases by the Company of shares for cancellation or to be held as Treasury shares, in accordance with the authority given by shareholders at the AGM in 2004.

In May 2004 the Company was authorised to purchase a maximum of 594.6 million shares (600 million shares in May 2003). During 2004 18 million shares were purchased for cancellation and 70 million shares were purchased to be held as Treasury shares (see Note 27 to the Financial statements, 'Share capital and share premium account' in the Company's Annual Report 2004). The exact amount and timing of future purchases, and the extent to which repurchased shares will be held as Treasury shares rather than being cancelled, will be determined by the Company and is dependent on market conditions and other factors.

SmithKline Beecham plc Floating Rate Unsecured Loan Stock 1990/2010

The loan stock is not listed on any exchange but holders may require SmithKline Beecham plc to redeem their loan stock at par, i.e. £1 for every £1 of loan stock held, on the first business day of March, June, September and December. Holders wishing to redeem all or part of their loan stock should complete the notice on the back of their loan stock certificate and return it to the registrar, to arrive at least 30 days before the relevant redemption date.

Cautionary statement

Under the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995, the Company cautions investors that any forwardlooking statements or projections made by the Company, including those made in this Annual Review, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Legal proceedings' and 'Risk factors' in the Company's Annual Report 2004.

Financial reporting

RESULTS ANNOUNCEMENTS
Results Announcements are issued to the London Stock Exchange, and made available on their news service, and at the same time, or shortly afterwards, they are issued to the media, are made available on the website and are submitted to the Securities and Exchange Commission in the US and the New York Stock Exchange.

FINANCIAL REPORTS
The Company publishes an Annual Report and, for the investor not needing the full detail of the Report, an Annual Review. These are available on the GSK website. The Annual Review is sent to all shareholders on the date of publication. Shareholders may also elect to receive the Report by writing to the Company's registrars. Alternatively, shareholders may elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk. Copies of previous financial reports are available on the website. Printed copies can be obtained from the Registrar in the UK and from the Customer Response Center in the US.

PUBLICATIONS
This year, GSK is again producing a Corporate Responsibility Report covering performance in areas including community investment, business ethics and integrity, access to medicines, R&D and environment health and safety. The report will be published on the website at the end of March.

Share price

The table above sets out the middle market closing prices derived from the London Stock Exchange Daily Official List. The Company's share price decreased by 5% in 2004 from a price of £12.80 at 1 January 2004 to £12.22 at 31 December 2004. This compares with an increase in the FTSE 100 index of 8% during the year.

MARKET CAPITALISATION
The market capitalisation of GSK at 31 December 2004 was £72 billion. At that date GSK was the fourth largest company by market capitalisation on the FTSE index.

Dividends

GSK pays dividends quarterly.

The Board has declared dividends for 2004 as follows:

As a guide to holders of ADRs, the table below sets out the dividends paid per ADS in US dollars in the last five years. The dividends are adjusted for UK tax credit less withholding tax, where applicable, and are translated into US dollars at applicable exchange rates.

Since 6 April 1999, claims for refunds of tax credits on dividends from the UK tax authorities are of negligible benefit to US shareholders.

Dividends paid to Glaxo Wellcome and SmithKline Beecham ADR holders are expressed as dividends per GSK ADS.

DIVIDEND CALENDAR

Annual General Meeting 2005

The Annual General Meeting will be held at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1P 3EE on 25 May 2005.